Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Capital Markets

<p>WuXi Biologics, a CRO/contract manufacturer focused on biologics, has filed an Application Proof with the HKEX for a new listing.  The document does not include a price range or proposed valuation, but previous news reports claimed a target valuation of US$1.5 billion and a US$300 million offering. This Insight will provide an overview of the company and sector. In addition, numerous Insights and related discussion of the listing of <a href="https://www.smartkarma.com/entities/22932" target="_blank" data-smartkarma-citation="entities:22932:1">Samsung Biologics Co., Ltd (207940 KS)</a> will provide additional information. We will follow up with a view on the proposed valuation and other matters closer to the offering.</p>

WuXi Biologics, a CRO/contract manufacturer focused on biologics, has filed an Application Proof with the HKEX for a new listing.  The document does not include a price range or proposed valuation, but previous news reports claimed a target valuation of US$1.5 billion and a US$300 million offering. This Insight will provide an overview of the company and sector. In addition, numerous Insights and related discussion of the listing of Samsung Biologics Co., Ltd (207940 KS) will provide additional information. We will follow up with a view on the proposed valuation and other matters closer to the offering.

China

WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland.  We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions. 

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Wuxi Biologics (2269 HK)

An Early Look at WuXi Biologics

WuXi Biologics, a CRO/contract manufacturer focused on biologics, has filed an Application Proof with the HKEX for a new listing. The document...

Kemp Dolliver, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)